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Introduction 
Primary systemic amyloidosis, also known as 
immunoglobulin light chain (AL) amyloidosis, is 
caused by clonal plasma cells that produce 
misfolded, amyloidogenic light-chains, which 
deposit systemically resulting in organ dysfunction. 
Although AL amyloidosis is the most common type 
of amyloidosis, the incidence of systemic AL 
amyloidosis is rare, estimated at 8.9 per million 
annually [1]. Cutaneous symptoms manifest in 30-
40% of patients with primary systemic amyloidosis 
and can provide the first diagnostic clues in 
Abstract 
The diagnosis of primary systemic amyloidosis, also 
known as AL (amyloid light-chain) amyloidosis, is 
often delayed owing to its nonspecific 
manifestations as well as its rarity. A 64-year-old 
woman presented with an eight-month history of 
significant weight loss, anemia, fatigue, and 
progressive painful cutaneous lesions on her hands, 
lips, back, perianal, and vulvar area that were 
originally treated unsuccessfully with antimalarials 
and systemic corticosteroids. Histopathological 
examination revealed an amorphous dermis with 
pale pink material that demonstrated positive 
birefringence with Congo red staining. 
Subsequently, the patient underwent a bone marrow 
biopsy, which uncovered a plasma cell myeloma, the 
source of her amyloidogenic protein production.   
 
 
Figure 1. A) Diffuse skin-colored palpable firm nodules on the 
back. B) Pink firm pedunculated papules on lower labial mucosa. 
Lower lips are grossly hypertrophied and filled by palpable 
infiltrative plaques. 
B
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discovering an underlying systemic 
pathophysiology [2]. 
Case Synopsis 
A 64- year-old woman, with an eight-month history 
of significant weight loss, anemia, fatigue, and 
progressive painful cutaneous lesions on her hands, 
lips, back, and perianal and vulvar areas was 
admitted for syncope and work up of hematologic 
malignancy. Her past medical history included 
coronary artery disease and carpal tunnel surgery 
performed five years prior to admission. A 
dermatology consultation was requested for her skin 
lesions. Lesions originally began on two fingers on 
the patient’s right hand and several more very 
painful, enlarging and hardened plaques 
subsequently developed on the lower lips, vulva, 
perianal region, abdomen, and back. The patient 
reported having taken oral prednisone 5mg daily 
and hydroxychloroquine 200mg twice daily for two 
years for a diagnosis of “autoimmune inflammation.” 
On physical examination, the patient had numerous 
yellow-to-skin-colored indurated plaques and 
nodules on the upper eyelids, upper back, right 
index and third lateral fingers, abdomen, and vulvar 
and perianal regions (Figures 1-3). Our patient also 
had 12-50mm firm infiltrative plaques on the lower 
lip with yellow papules on the labial mucosae 
(Figure 1B). These lesions covered a total body 
surface area greater than 10%. Also noted were 30-
60mm ecchymotic patches on the arms, hands, and 
upper thighs. 
A 4mm punch biopsy was performed on the 
indurated plaque on the lower lip, along with a shave 
biopsy on a softer plaque on the right index finger. 
Microscopic findings displayed compact 
orthokeratosis overlying a hypocellular and 
amorphous dermis in which pale pink material 
appeared to have replaced a majority of the dermal 
 
 
Figure 2. A) Skin colored to yellow firm plaques on lateral 
aspects of fingers. B) Yellow papules coalescing into plaques on 
upper and lower eyelids. B 
 
 
Figure 3. A) Discrete firm papules infiltrating edge of labia 
majora and large ecchymotic plaques on upper inner thighs. B) 
Firm plaques with erythema infiltrating entire perirectal region. 
A 
B 
B
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collagen (Figure 4A). Perivascular collagenous 
deposits were also noted (Figure 4A). Congo red 
stain demonstrated weak but positive birefringence 
in the thick hyaline material deposited within the 
dermis (Figure 4B). Based on these findings, the 
patient underwent a bone marrow biopsy, which 
showed an infiltration of the marrow with a 
monoclonal population of plasma cells, comprising 
57% of the total cells. Flow cytometric analysis of 
aspirated bone marrow revealed a distinct plasma 
cell population with an intracytoplasmic lambda 
light chain restriction. 
Hematology investigations demonstrated anemia, 
an abnormal kappa-to-lambda ratio of 0 (reference 
0.26-1.65), and remarkably elevated free kappa light 
chain of 29.96mg/L (reference 3.3-19.4mg/L) and 
free lambda light chain of 9466mg/L (reference 5.7-
26.3mg/L). No M spike was detected on serum 
protein electrophoresis. The patient’s other blood 
tests did not show deterioration in renal or hepatic 
function. However, she was found to have nephrotic 
range proteinuria of 2.4g/day (normal range 
<150mg/day). Radiographic results, including a 
bone survey, were negative. Echocardiography and 
electrocardiogram findings were also normal. 
Calcium was within normal limits. 
Based on our patient’s clinical findings, biopsy, and 
hematological results, a diagnosis of primary 
systemic amyloidosis resulting from plasma cell 
myeloma was made. She was started on the CyBorD 
chemotherapy regimen consisting of: 
cyclophosphamide 900mg/m2 on day 1, bortezomib 
1.3mg/m2 SQ on days 1, 4, 8, 11, and dexamethasone 
40mg PO days 1, 4, 8, 11. The patient was discharged 
on day 11 of her chemotherapy regimen and 
returned to her local hematologist/ oncologist for 
the remainder of therapy. The patient was lost to 
follow up. 
 
Case Discussion 
In primary systemic amyloidosis, a population of 
clonal plasma cells produce monoclonal light chains 
that form fibrils with a ß-pleated sheet configuration 
that are then deposited in various tissues. 
Immunoglobulin light chain amyloidosis can occur 
alone or in association with multiple myeloma, 
Waldenström macroglobulinemia, or non-Hodgkin 
lymphoma [3, 4]. Cutaneous involvement occurs in 
approximately 30%-40% of systemic AL amyloidosis 
patients, usually presenting as purpuric to skin 
colored, waxy papules, plaques, and nodules 
affecting the scalp, face, flexural areas, genitalia, and 
periorbital regions [2]. The infiltration of amyloid into 
superficial blood vessels often presents as non-
traumatic purpura and ecchymosis, particularly on 
the face, particularly the periorbital regions. Bilateral 
periorbital ecchymosis or “raccoon eyes” is highly 
characteristic and should raise suspicion for 
amyloidosis [5]. There have also been case reports of 
AL amyloidosis causing bullous and hemorrhagic 
 
 
 
 
Figure 4. A) Hypocellular dermis in which hyalinized pale pink 
amorphous material appears to have replaced a majority of 
dermal collagen. Vascular structures have retained perivascular 
collagenous deposits. H&E, 10×. B) Shave biopsy from the lower 
lip with Congo red stain highlighting positive birefringence in the 
thick hyaline material deposited within the dermis, 20×. 
A 
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lesions, cutis laxa, scalp lesions resembling cutis 
verticis gyrata, nail dystrophies, alopecia, and 
scleroderma-like infiltrative plaques [6-12]. Patients 
with AL amyloidosis present with a wide range of 
associated symptoms, including weight loss, fatigue, 
syncope, peripheral edema, peripheral neuropathy, 
carpal tunnel syndrome, and cutaneous symptoms. 
For a patient with suspected AL amyloidosis, initial 
evaluation includes a fat pad aspirate or rectal 
biopsy, bone marrow biopsy, and workup for light 
chain abnormalities [13]. Routine workup for light 
chain abnormalities includes ratio analysis of serum 
free light chain and serum protein electrophoresis 
with immunofixation. Hematoxylin and eosin- 
stained sections from the biopsy should 
demonstrate amorphous, eosinophilic masses 
characteristic of amyloid deposition. With Congo red 
stain, amyloid deposits show a characteristic apple 
green birefringence under polarized light [13]. 
Persistent Congo-red positivity after treatment with 
potassium permanganate is specific for AL 
amyloidosis [14]. 
Primary systemic amyloidosis without treatment has 
a median survival of approximately 12 months [15]. 
Treatment designs are aimed at eliminating light 
chain production and typically utilize cytotoxic 
agents such as mephalan, bortezomib, and 
cyclophosphamide [16]. Despite improvements in 
treatment prognosis is poor in general. 
Diagnosis of this disease is often delayed owing to its 
nonspecific manifestations as well as its rarity. 
Cutaneous presentations of primary systemic 
amyloidosis have been misdiagnosed as 
scleroderma, squamous cell carcinoma, or other 
conditions [9, 17, 18]. In the case of our patient, the 
infiltrative yellow plaques on the eyelids initially 
raised suspicion for necrobiotic xanthogranuloma and 
other xanthomatous disorders in the initial 
differential diagnosis. However, the diffuse nature of 
the mucocutaneous amyloid deposition pointed to a 
possible underlying systemic infiltrative process. The 
hematological workup included bone marrow 
biopsy, which then confirmed monoclonality with 
restriction of free lambda light chains. 
 
Conclusion 
This case demonstrates the classical cutaneous 
manifestations of primary systemic amyloidosis, 
particularly the generalized infiltrative plaques and 
ecchymosis. It highlights the inconspicuous nature 
of plasma cell dyscrasia and the importance of 
initiating appropriate malignancy work up in a time-
sensitive fashion upon recognition of these 
cutaneous findings. 
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